{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:13:52Z","timestamp":1780470832172,"version":"3.54.1"},"reference-count":32,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Background Cytomegalovirus (CMV) infection is a major contributor to morbidity and mortality in recipients of hematopoietic stem cell transplant (HSCT), solid organ transplant (SOT), and chimeric antigen receptor T-cell (CAR-T) therapy. While antiviral agents remain the cornerstone of treatment, CMV-specific immunoglobulins (CMVIG) have been utilized as adjunct therapy with variable outcomes. This study aims to evaluate the virological response and tolerability of CMVIG in cases of severe or refractory CMV viremia, with or without CMV disease. Methods: We conducted a single-center retrospective case series of adult recipients of SOT, allogeneic HSCT, and\/or CAR-T cell therapy who developed CMV viremia or disease and received at least one dose of CMVIG between May 2017 and May 2023 at our center. Virological improvement within 14 days of starting CMVIG and tolerability of CMVIG are the primary outcome of this study. Results: A total of 33 patients were included. Of these, 29 underwent transplantation [SOT: 48.2%, HSCT: 51.7%], and five underwent CAR-T cell therapy (one post-HSCT). High-risk CMV serostatus was present in 12%. CMV viremia was documented in 32 patients (97%), and tissue-invasive disease was present in 11 patients (33.3%). Virological response, was observed in 65.6% of the cohort. The median time to undetectable CMV viral load following CMVIG initiation was 28 days. CMVIG was well-tolerated. All-cause mortality at 90 days remained high (57%). Conclusion: In this case series, CMVIG demonstrated a virological response rate of 65.6% in patients with severe or refractory CMV infection. While CMVIG was well-tolerated with minimal adverse events, the high mortality rate despite virological response suggests that CMVIG may be insufficient for this critically ill population. Our findings should be interpreted as observational data from a small case series, and prospective controlled trials are needed to establish the true benefit of CMVIG in combination with standard antiviral therapy.<\/jats:p>","DOI":"10.3390\/v18060599","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T10:19:52Z","timestamp":1779877192000},"page":"599","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Use of Cytomegalovirus Immunoglobulin with Antiviral Therapy for Cytomegalovirus Infection in Transplant Recipients: A Tertiary Care Single-Center Experience"],"prefix":"10.3390","volume":"18","author":[{"given":"Reem M.","family":"Alameer","sequence":"first","affiliation":[{"name":"Section of Transplant Infectious Diseases, Organ Transplant Center of Excellence, King Faisal Specialist Hospital and Research Center, Makkah Al Mukarramah Branch Road, Al Maather, Riyadh 12713, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bayan","family":"Alamro","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Internal Medicine Department, King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khulud","family":"Alanazi","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Internal Medicine Department, King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Alahmari","sequence":"additional","affiliation":[{"name":"Department of Hematology, Stem Cell Transplantation & Cellular Therapy, Cancer Centre of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghadeer","family":"Almousa","sequence":"additional","affiliation":[{"name":"Pharmaceutical Care Division, King Faisal Specialist Hospital and Research Center, Riyadh 12713, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4920-3741","authenticated-orcid":false,"given":"Abdullah","family":"Almohaizeie","sequence":"additional","affiliation":[{"name":"Pharmaceutical Care Division, King Faisal Specialist Hospital and Research Center, Riyadh 12713, Saudi Arabia"},{"name":"College of Pharmacy, Alfaisal University, Riyadh 11533, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadeel","family":"Samarkandi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Stem Cell Transplantation & Cellular Therapy, Cancer Centre of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem S.","family":"Almaghrabi","sequence":"additional","affiliation":[{"name":"Section of Transplant Infectious Diseases, Organ Transplant Center of Excellence, King Faisal Specialist Hospital and Research Center, Makkah Al Mukarramah Branch Road, Al Maather, Riyadh 12713, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1083-8791(03)00287-8","article-title":"Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies","volume":"9","author":"Boeckh","year":"2003","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1097\/TP.0000000000000160","article-title":"Cytomegalovirus serology and replication remain associated with solid organ graft rejection and graft loss in the era of prophylactic treatment","volume":"98","author":"Stern","year":"2014","journal-title":"Transplantation"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s40265-018-0943-1","article-title":"New Developments in the Management of Cytomegalovirus Infection After Transplantation","volume":"78","author":"Meesing","year":"2018","journal-title":"Drugs"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1086\/528718","article-title":"Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation","volume":"46","author":"Arthurs","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40121-017-0180-z","article-title":"Who Is the Patient at Risk of CMV Recurrence: A Review of the Current Scientific Evidence with a Focus on Hematopoietic Cell Transplantation","volume":"7","author":"Styczynski","year":"2018","journal-title":"Infect. Dis. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/tid.12428","article-title":"Opportunistic infections complicating solid organ transplantation with alemtuzumab induction","volume":"17","author":"Helfrich","year":"2015","journal-title":"Transpl. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1182\/bloodadvances.2024012922","article-title":"Incidence and outcomes of cytomegalovirus reactivation after chimeric antigen receptor T-cell therapy","volume":"8","author":"Lin","year":"2024","journal-title":"Blood Adv."},{"key":"ref_8","first-page":"1","article-title":"Cytomegalovirus diseases after hematopoietic stem cell transplantation: A mini-review","volume":"342","author":"Nesher","year":"2014","journal-title":"Cancer Lett."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eimc.2009.07.008","article-title":"Direct and indirect effects of cytomegalovirus: Can we prevent them?","volume":"28","author":"Razonable","year":"2010","journal-title":"Enfermedades Infecc. Microbiol. Clin."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1097\/TP.0b013e3181ff1493","article-title":"Extended valganciclovir prophylaxis in D+\/R\u2212 kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: Two-year results of the IMPACT study","volume":"90","author":"Humar","year":"2010","journal-title":"Transplantation"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/cid\/ciy696","article-title":"Definitions of Resistant and Refractory Cytomegalovirus Infection and Disease in Transplant Recipients for Use in Clinical Trials","volume":"68","author":"Chemaly","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1055\/s-2008-1067585","article-title":"Hyperimmunoglobulin treatment in CMV infections following heart transplantation","volume":"113","author":"Cremer","year":"1988","journal-title":"Dtsch. Med. Wochenschr."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"NP101","DOI":"10.1177\/11206721221112802","article-title":"Cytomegalovirus immunoglobulin therapy for CMV retinitis post hematopoietic stem cell transplantation","volume":"33","author":"Chiu","year":"2022","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1111\/j.1600-6143.2011.03519.x","article-title":"Cytomegalovirus prostatitis in a heart transplant recipient","volume":"11","author":"Rouphael","year":"2011","journal-title":"Am. J. Transpl."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1097\/TP.0000000000001097","article-title":"CMV Immunoglobulins for the Treatment of CMV Infections in Thoracic Transplant Recipients","volume":"100","author":"Schulz","year":"2016","journal-title":"Transplantation"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1038\/s41409-018-0166-9","article-title":"Cytotect\u00aeCP as salvage therapy in patients with CMV infection following allogeneic hematopoietic cell transplantation: A multicenter retrospective study","volume":"53","author":"Alsuliman","year":"2018","journal-title":"Bone Marrow Transplant."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1592\/phco.30.6.554","article-title":"Use of Cytomegalovirus Intravenous Immune Globulin for the Adjunctive Treatment of Cytomegalovirus in Hematopoietic Stem Cell Transplant Recipients","volume":"30","author":"Alexander","year":"2010","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"ref_20","first-page":"132","article-title":"A randomized trial of high dose polyvalent intravenous immunoglobulin (HDIgG) vs. Cytomegalovirus (CMV) hyperimmune IgG in allogeneic hemopoietic stem cell transplants (HSCT)","volume":"83","author":"Zikos","year":"1998","journal-title":"Haematologica"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1097\/TP.0000000000001095","article-title":"The Immunology of Posttransplant CMV Infection: Potential Effect of CMV Immunoglobulins on Distinct Components of the Immune Response to CMV","volume":"100","author":"Carbone","year":"2016","journal-title":"Transplantation"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1399-0012.2007.00750.x","article-title":"CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: A meta-analysis","volume":"22","author":"Bonaros","year":"2008","journal-title":"Clin. Transpl."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Barten, M.J., Baldanti, F., Staus, A., H\u00fcber, C.M., Glynou, K., and Zuckermann, A. (2022). Effectiveness of Prophylactic Human Cytomegalovirus Hyperimmunoglobulin in Preventing Cytomegalovirus Infection following Transplantation: A Systematic Review and Meta-Analysis. Life, 12.","DOI":"10.3390\/life12030361"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e13733","DOI":"10.1111\/tid.13733","article-title":"Management of ganciclovir resistance cytomegalovirus infection with CMV hyperimmune globulin and leflunomide in seven cardiothoracic transplant recipients and literature review","volume":"24","author":"Santhanakrishnan","year":"2022","journal-title":"Transpl. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_26","unstructured":"Abbott Molecular (2022). Alinity m CMV Assay, Abbott Diagnostics."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e13754","DOI":"10.1111\/tid.13754","article-title":"Use of anti-CMV immunoglobulins in lung transplant recipients: The French experience","volume":"23","author":"Charlotte","year":"2021","journal-title":"Transpl. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e13512","DOI":"10.1111\/ctr.13512","article-title":"Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Razonable","year":"2019","journal-title":"Clin. Transpl."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e14183","DOI":"10.1111\/tid.14183","article-title":"Slaying the \u201cTroll of Transplantation\u201d-new frontiers in cytomegalovirus management: A report from the CMV International Symposium 2023","volume":"26","author":"Kotton","year":"2024","journal-title":"Transpl. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.cmi.2022.07.001","article-title":"Cytomegalovirus infection in transplant recipients: Newly approved additions to our armamentarium","volume":"29","author":"Khawaja","year":"2023","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.2147\/DDDT.S265644","article-title":"Current Perspectives on Letermovir and Maribavir for the Management of Cytomegalovirus Infection in Solid Organ Transplant Recipients","volume":"18","author":"Razonable","year":"2024","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e13655","DOI":"10.1111\/ctr.13655","article-title":"The use of CMVIg rescue therapy in cardiothoracic transplantation: A single-center experience over 6 years (2011\u20132017)","volume":"33","author":"Santhanakrishnan","year":"2019","journal-title":"Clin. Transpl."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/6\/599\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:23:33Z","timestamp":1780467813000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/6\/599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":32,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["v18060599"],"URL":"https:\/\/doi.org\/10.3390\/v18060599","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]}}}